Tryptamine Therapeutics Partners with Lucid Health to Advance TRP-8803's Product Registration in Australia

MT Newswires Live06-19

Tryptamine Therapeutics (ASX:TYP) is advancing the product registration and reimbursement strategy in Australia for its neuropsychiatric disorder treatment TRP-8803 by appointing advisory group Lucid Health Consulting to assist it with the process, according to a Wednesday filing with the Australian Securities Exchange.

The two parties will begin engagement on July 1, allowing Lucid Health to participate in ongoing talks with the Therapeutic Goods Administration.

TRP-8803 is an IV-infused psilocin aimed to treat certain neuropsychiatric disorders. Potential benefits include a reduction in the onset of the psychedelic state, more precise control of the depth and duration of the experience, and a shorter intervention to a commercially feasible timeframe, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444641393?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-19 11:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444641393","market":"hk","top_or_hot":-1,"title":"Tryptamine Therapeutics Partners with Lucid Health to Advance TRP-8803's Product Registration in Australia","media":"MT Newswires Live","content":"<html><body><p> Tryptamine <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:TYP) is advancing the product registration and reimbursement strategy in Australia for its neuropsychiatric disorder treatment TRP-8803 by appointing advisory group Lucid Health Consulting to assist it with the process, according to a Wednesday filing with the Australian Securities Exchange.</p><p>The two parties will begin engagement on July 1, allowing Lucid Health to participate in ongoing talks with the Therapeutic Goods Administration.</p><p>TRP-8803 is an IV-infused psilocin aimed to treat certain neuropsychiatric disorders. Potential benefits include a reduction in the onset of the psychedelic state, more precise control of the depth and duration of the experience, and a shorter intervention to a commercially feasible timeframe, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tryptamine Therapeutics Partners with Lucid Health to Advance TRP-8803's Product Registration in Australia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTryptamine Therapeutics Partners with Lucid Health to Advance TRP-8803's Product Registration in Australia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-19 11:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tryptamine Therapeutics (ASX:TYP) is advancing the product registration and reimbursement strategy in Australia for its neuropsychiatric disorder treatment TRP-8803 by appointing advisory group Lucid ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2444641393","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444641393","pubTimestamp":1718766282,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tryptamine Therapeutics  is advancing the product registration and reimbursement strategy in Australia for its neuropsychiatric disorder treatment TRP-8803 by appointing advisory group Lucid Health Consulting to assist it with the process, according to a Wednesday filing with the Australian Securities Exchange.The two parties will begin engagement on July 1, allowing Lucid Health to participate in ongoing talks with the Therapeutic Goods Administration.TRP-8803 is an IV-infused psilocin aimed to treat certain neuropsychiatric disorders. Potential benefits include a reduction in the onset of the psychedelic state, more precise control of the depth and duration of the experience, and a shorter intervention to a commercially feasible timeframe, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","BK4144":"石油与天然气的储存和运输","IE00BMG7P587.USD":"LEGG MASON CLEARBRIDGE GLOBAL INFRASTRUCTURE INCOM \"A\" (USD) INC","BK4099":"汽车制造商","IE00BMG7P819.SGD":"Legg Mason ClearBridge - Global Infrastructure Income A Mdis SGD-H Plus","BK4551":"寇图资本持仓","IE00BMG7P926.USD":"Legg Mason ClearBridge - Global Infrastructure Income A Acc USD","TYP.AU":"Tryptamine Therapeutics Ltd","XKO.AU":"标普/澳交所 300指数","BK4566":"资本集团","LCID":"Lucid Group Inc","IE00BMG7P694.USD":"Legg Mason ClearBridge - Global Infrastructure Income A Mdis USD Plus","TRP":"TC Energy","BK4555":"新能源车","BK4139":"生物科技","XAO.AU":"标普/澳交所 普通股指数","LENZ":"Therapeutics","BK7096":"制药"},"translate_title":"Tryptamine Therapeutics与Lucid Health合作推进TRP-8803在澳大利亚的产品注册","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":1,"XJO.AU":1,"XAO.AU":1,"TRP":1,"LENZ":1,"LCID":1,"TYP.AU":0.9},"content_text":"Tryptamine Therapeutics (ASX:TYP) is advancing the product registration and reimbursement strategy in Australia for its neuropsychiatric disorder treatment TRP-8803 by appointing advisory group Lucid Health Consulting to assist it with the process, according to a Wednesday filing with the Australian Securities Exchange.The two parties will begin engagement on July 1, allowing Lucid Health to participate in ongoing talks with the Therapeutic Goods Administration.TRP-8803 is an IV-infused psilocin aimed to treat certain neuropsychiatric disorders. Potential benefits include a reduction in the onset of the psychedelic state, more precise control of the depth and duration of the experience, and a shorter intervention to a commercially feasible timeframe, the filing said.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444641393"}